Viatris (VTRS) said Saturday that it has entered into definitive agreements with Biocon to sell its equity stake in Biocon Biologics for $815 million.
Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued equity shares of Biocon, the company said.
The transaction is expected to close in Q1 of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments